article thumbnail

Likmez: First FDA-Approved Liquid Option of the Antibiotic Metronidazole

XTalks

Kesin Pharma has obtained approval from the US Food and Drug Administration (FDA) for its oral suspension antibiotic drug Likmez (metronidazole), designed for patients with dysphagia and difficulty swallowing. Likmez offers a safer alternative by mitigating the associated risks linked to off-label drug compounding.

article thumbnail

FDA approves first microbiome drug from Ferring Pharmaceuticals

STAT News

The Food and Drug Administration approved the first therapy using bacteria from stool samples to treat a bowel disorder on Wednesday, paving the way for several similar treatments in development.    The drug, called Rebyota, is given as a one-dose treatment for clostridium difficile infection s, commonly known as C.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis’ Fabhalta Gets FDA Approval for Rare Complement Blood Disorder

XTalks

After receiving US Food and Drug Administration (FDA) approval for Fabhalta (iptacopan) last week for the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH), Novartis presented trial data yesterday showing the drug’s promise in another indication.

article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). anthracis exposure. anthracis.

article thumbnail

Merck’s Next-Generation Pneumonia Vaccine Gets FDA Approval

XTalks

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. It has been one of Pfizer’s best-selling drugs.

article thumbnail

FDA Approves Rebyota as First Fecal Microbiome Therapy for Recurrent C. Difficile Infection

XTalks

Swiss company Ferring Pharmaceuticals has won a historic approval from the US Food and Drug Administration (FDA) for its fecal transplant-based therapy Rebyota (fecal microbiota, live-jslm) to reduce the recurrence of bacterial infection. The therapy is the first of its kind to be approved in the US. Difficile. “As

article thumbnail

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Pharmaceutical Technology

Biotechnology company Lumen Bioscience has secured fast track designation from the US Food and Drug Administration (FDA) for LMN-201 for the treatment and prevention of C difficile infection (CDI). It is compatible with standard-of-care antibiotics. Pivotal trials on LMN-201 are expected to commence in 2023. “We

Bacterium 130